Table 6 Cost inputs used in the China seroconversion model
Cost parameter | Annual cost ($) | Source | Utility | Source |
|---|---|---|---|---|
Heath state costs | ||||
Cured (HBsAg negative) | 1315.9 | Zhang et al. (2015) | 0.710 | Levy et al. (2008) |
Inactive carrier | 2237.5 | 0.710 | ||
Chronic hepatitis B | 2237.5 | 0.520 | ||
Compensated cirrhosis | 3468.5 | 0.570 | ||
Decompensated cirrhosis | 6449.3 | 0.260 | ||
Hepatocellular carcinoma | 9179.5 | 0.310 | ||
Liver transplant year 1 | 57,765.5 | 0.410 | ||
Liver transplant year 2+ | 9626.9 | 0.550 | ||
Drug costs | ||||
LAM | 710.41 | IMS PADDS database, cost of LAM is derived from Zhang et al. (2015); inflation adjusted | ||
ADV | 579.54 | |||
LDT | 1132.41 | |||
ETV | 1073.10 | |||
TDF | 2636.08 | |||
LDT + ADV | 1711.95 | |||
LDT + TDF | 3768.49 | |||
BSC | NA | |||
Renal Drug Cost (tacrolimus 0.25 mg daily; MMF 2 g daily, and prednisolone 30 mg daily for 90 days) | 2103 | IMS PADDS database 2015 | ||
Procedure costs | ||||
Dialysis (for CKD 5 patients) | 17,580 | Dialysis cost of $17,280 (Liu 2013) (adjusted for inflation) + monitoring cost of $300 | ||
Transplant (for CKD 5 patients) | 11,825 | Transplant cost of $11,525 (Zhao et al. 2012) (adjusted for inflation) + monitoring cost of $300 | ||
Cost per hospital visit (assumed as unit cost of physician visit in China)* | 25 | Chinese medical news website (Woodhead 2015) | ||
Annual examination costs | ||||
For all antiviral therapies | 169.01 | Zhang et al. (2015) | ||
For BSC | 175 | |||
Cost for evaluation of new patient | 169 | |||